A chimeric mouse model of Gaucher disease

被引:13
作者
Beutler, E [1 ]
West, C [1 ]
Torbett, BE [1 ]
Deguchi, H [1 ]
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
关键词
D O I
10.1007/BF03402150
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: There is a major need for a mouse model of Gaucher disease, but the glucocerebrosidase knockout mouse is not viable; it dies shortly before or immediately after birth, apparently because of involvement of the central nervous system and/or skin. The most common form of Gaucher disease, type I, has a phenotype that is limited to the monocyte-macrophage system. Materials and Methods: We have created a chimeric mouse by infusing hematopoietic stem cells from fetuses that are homozygous for the glucocerebrosidase knockout into irradiated mice. Results: The chimeric mice manifested a severe deficiency of glucocerebrosidase activity in peripheral blood cells and spleen indicating a lack of cell-cell correction. Levels of glucocerebroside in spleen and liver are increased, and infusing the mice with exogenous glucocerebroside/albumin particles produced a marked increase in the amount of glucocerebroside stored in liver and spleen. Morphologically identifiable Gaucher cells were not present. Conclusions: The chimeric model reflects the increased glycolipid storage in the reticuloendothelial system that is characteristic of Gaucher disease, and could be useful as a model for studying treatment of Gaucher disease.
引用
收藏
页码:247 / 250
页数:4
相关论文
共 17 条
[1]  
ADACHI M, 1977, ARCH PATHOL LAB MED, V101, P255
[2]   ACCUMULATION OF TISSUE GLUCOSYLSPHINGOSINE IN GAUCHER-LIKE MOUSE INDUCED BY THE GLUCOSYLCERAMIDASE INHIBITOR CYCLOPHELLITOL [J].
ATSUMI, S ;
NOSAKA, C ;
IINUMA, H ;
UMEZAWA, K .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 304 (01) :302-304
[3]  
BARTON NW, 1975, J BIOL CHEM, V250, P3966
[4]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - MACROPHAGE-TARGETED GLUCOCEREBROSIDASE FOR GAUCHERS-DISEASE [J].
BARTON, NW ;
BRADY, RO ;
DAMBROSIA, JM ;
DIBISCEGLIE, AM ;
DOPPELT, SH ;
HILL, SC ;
MANKIN, HJ ;
MURRAY, GJ ;
PARKER, RI ;
ARGOFF, CE ;
GREWAL, RP ;
YU, KT .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (21) :1464-1470
[5]   IDENTIFICATION OF THE 2ND COMMON JEWISH GAUCHER DISEASE MUTATION MAKES POSSIBLE POPULATION-BASED SCREENING FOR THE HETEROZYGOUS STATE [J].
BEUTLER, E ;
GELBART, T ;
KUHL, W ;
SORGE, J ;
WEST, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) :10544-10547
[6]  
BEUTLER E, 1997, BAILLIERE CLIN HAEM, V10, P711
[7]  
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[8]   Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis [J].
Cox, T ;
Lachmann, R ;
Hollak, C ;
Aerts, J ;
van Weely, S ;
Hrebícek, M ;
Platt, F ;
Butters, T ;
Dwek, R ;
Moyses, C ;
Gow, I ;
Elstein, D ;
Zimran, A .
LANCET, 2000, 355 (9214) :1481-1485
[9]   Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway [J].
Deguchi, H ;
Fernández, JA ;
Pabinger, I ;
Heit, JA ;
Griffin, JH .
BLOOD, 2001, 97 (07) :1907-1914
[10]   Gene therapy for genetic haematological disorders and immunodeficiencies [J].
Kohn, DB .
JOURNAL OF INTERNAL MEDICINE, 2001, 249 (04) :379-390